Shanghai Sigma-Audley New Material Technology: difference between revisions
Diff·revision 12 → 13·16:50, 15 Mar 2025
Difference between revision 12 and revision 13 of Shanghai Sigma-Audley New Material Technology. 10 lines changed; the page grew by 507 bytes.
| Revision 12 — 03:32, 2 Mar 2025 SortKeySascha (talk) split overlong sentence 7,016 bytes +347 | Revision 13 — 16:50, 15 Mar 2025 COA_Colwyn (talk) add the registered legal name exactly as it appears in the registry record 7,523 bytes +507 | ||
|---|---|---|---|
| 49 | Documentation detail reported by purchasers is markedly better for the incretin analogues than for the bulk categories, a gradient visible across most organisations covered on this wiki and probably reflecting where purchaser scrutiny is concentrated.{{r|reports}} | 49 | Documentation detail reported by purchasers is markedly better for the incretin analogues than for the bulk categories, a gradient visible across most organisations covered on this wiki and probably reflecting where purchaser scrutiny is concentrated.{{r|reports}} |
| 50 | 50 | ||
| + | 51 | == Independent testing record == | |
| + | 52 | Submitted reports on SSA material to July 2026 are concentrated on tirzepatide and semaglutide, with a smaller set on repair peptides. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties, and where a certificate accompanied the sample the two figures have generally been close.{{r|reports}} | |
| + | 53 | ||
| 51 | == References == | 54 | == References == |
| 52 | {{reflist}} | 55 | {{reflist}} |
| ⋮ | ⋮ | ||
| 57 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 60 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 58 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | 61 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> |
| + | 62 | ||
| + | 63 | == See also == | |
| + | 64 | * [[Certificate of analysis]] | |
| + | 65 | * [[Third-party testing]] | |
| + | 66 | * [[Area percent purity]] | |
| + | 67 | * [[Peptide content]] | |
| + | 68 | * [[Research use only]] | |
| 59 | 69 | ||
| 60 | {{DEFAULTSORT:Shanghai Sigma-Audley New Material Technology}} | 70 | {{DEFAULTSORT:Shanghai Sigma-Audley New Material Technology}} |